April 2026 Research Update

This month added a clearer real-world picture of what sutimlimab does well and what it may not fully address. Across routine-care experience, hemoglobin and lab signs of red blood cell breakdown improved quickly and stayed improved for many patients, while cold-induced symptoms in the hands and feet often did not improve even when blood counts did. [1]

In an international cohort of 57 adults, hemoglobin rose within 2 weeks and reached about 12 g/dL by 4 weeks, with stability reported out to 24 months. The study also noted that people with ongoing cold-induced symptoms tended to have lower response rates, and that infections occurred in 23% of patients, with severe infections mostly seen in people who had previously received rituximab. [1]

A single case report described a person with CAD and an enlarged, overactive spleen (hypersplenism) who improved after spleen removal and then resumed sutimlimab. The report raises the possibility that in some individuals, problems like hypersplenism may contribute to poor response until they are addressed, but this remains an early observation from one patient. [2]

For many patients, these studies strengthen the expectation that sutimlimab (a complement pathway blocker) can improve anemia quickly and maintain that improvement in real-world use, not only in tightly controlled trials. At the same time, they make it clearer that some day-to-day cold-triggered symptoms may persist even when hemoglobin improves, which may help explain why someone can feel only partly better. The infection findings matter now because they describe what was observed in routine care (including in previously treated people), but they do not prove sutimlimab caused the infections or predict what will happen for any one person. [1]

The single-patient splenectomy report is mainly a research signal rather than a general lesson. It suggests that when CAD is complicated by an overactive spleen, the drivers of low blood counts might be more than one process, and some people may not fit a simple "one treatment fixes all" pattern. Because it is one case, it cannot show how often this happens or who might respond similarly. [2]

This month, studies looking inside the bone marrow highlighted that CAD often sits on a spectrum with small B-cell clones and, in some people, clearer B-cell cancers. The consistent message was that careful testing can change how a case is categorized, and that relying only on what the marrow looks like under the microscope may miss clonal signals that other tests detect. [3]

In a retrospective review of 56 people with cold-type autoimmune hemolytic anemia, 10 were reclassified as having overt B-cell malignancies causing cold agglutinin syndrome. Among the remaining patients considered CAD, almost all had evidence of B-cell clonality in the marrow (98%), many had an M-protein (89%), and all tested cases were MYD88 wild-type, while only 11% met strict WHO-HAEM5 morphology criteria for CAD-related marrow changes. [3]

A Japanese cohort that used combined clinical, tissue, and molecular evaluation also found that classification can shift with deeper testing. Of 13 patients who underwent detailed workup, 9 were ultimately classified as primary CAD, and the authors emphasized that primary CAD itself can look heterogeneous across patients even after trying to exclude secondary causes. [4]

For patients and caregivers, these studies help explain why the workup for CAD can feel complex and why results may be described as "a small B-cell clone" even when there is no obvious lymphoma diagnosis. They also show that in some people, more complete evaluation can uncover an underlying B-cell cancer that changes the label from primary CAD to cold agglutinin syndrome related to another condition. This information matters mainly for understanding diagnosis and prognosis research, since these papers did not test which evaluation approach leads to better outcomes for patients. [3]

What remains uncertain is how best to define and standardize the boundary between primary CAD and related B-cell disorders across hospitals and countries. These results support the idea that sensitive clonality testing and molecular features can add important context beyond microscope appearance, but they do not yet provide a single, universally accepted set of criteria that fits everyone. [4]

This month’s case reports mainly reinforced how varied cold agglutinin problems can be, depending on the trigger and the person’s underlying health. They also show that the same outward problem (red blood cell clumping and hemolysis) can come from different causes, so the clinical story matters as much as the blood test. [5] [6] [2]

One report described cold agglutinin syndrome linked to an underlying marginal zone lymphoma, where rituximab alone did not work but rituximab plus lenalidomide led to a negative cold agglutinin test after four cycles and complete remission maintained for 24 months. This illustrates that in secondary cases tied to lymphoma, treating the lymphoma can go along with improvement in cold agglutinin findings. [5]

Another report described cold agglutinin syndrome triggered by Mycoplasma pneumoniae after a respiratory infection, with severe hemolysis and jaundice requiring supportive care and multiple transfusions. This case highlights that infections can sometimes trigger a temporary but serious cold agglutinin problem that is different from primary CAD. [6]

A third report focused on refractory CAD with hypersplenism, where spleen removal was followed by hematologic recovery and the ability to resume sutimlimab without reported complications in that individual. This points to the possibility that spleen-related blood cell trapping can complicate the picture in selected patients, but it is not evidence of a general approach. [2]

For patients, these reports are most useful for understanding the range of real-life situations that can sit under the "cold agglutinin" umbrella, including infection-triggered episodes and cases driven by a lymphoma. Because each report is a single person, they mainly help with awareness and questions to discuss, rather than predicting what will happen to others. [5]

These cases may matter most later, as more reports and registries accumulate and researchers can see which patterns repeat across many people. Right now, they clarify that cause and context (infection, lymphoma, spleen involvement) can strongly shape the course and the type of treatment used, but they do not establish which options work best on average. [2]